Recurrence patterns among patients with sinonasal mucosal melanoma: A multi‐institutional study

Pandrangi, Vivek; Mace, Jess C.; Abiri, Arash; Adappa, Nithin D.; Beswick, Daniel M.; Chang, Eugene H.; Eide, Jacob G.; Fung, Nicholas; Hong, Michelle K.; Johnson, Brian J.; Kohanski, Michael A.; Kshirsagar, Rijul S.; Kuan, Edward C.; Le, Christopher H.; Lee, Jivianne T.; Nabavizadeh, Seyed Ali; Obermeyer, Isaac P.; Palmer, James N.; Pinheiro‐Neto, Carlos D.; Smith, Timothy L.; Snyderman, Carl H.; Suh, Jeffrey D.; Wang, Eric; Wang, Marilene B.; Choby, Garret; Geltzeiler, Mathew

doi:10.1002/alr.23204

Cited by 5 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among patients with distant recurrence, immunotherapy was associated with improved 12-month postrecurrence survival (immunotherapy: 61.7% vs no immunotherapy: 33.3%, P = .02). 65 Sayed et al compared 17 SNMM patients with Ipilimumab immunotherapy treatment to 55 patients without and reported 3-year OS for patients with immunotherapy was 51% while the 3-year OS for patients without immunotherapy was 52% (95% CI: −29% to 32%). 51 Although Sayed et al reported no change in survival, they argued that immunotherapy was still benefiting survival because immunotherapy was only given to patients with metastatic and/or recurrent disease.…”

Section: Adjuvant and Salvage Immunotherapy Outcomes And Response Ratementioning

confidence: 99%

Immunotherapy in the Management of Sinonasal Mucosal Melanoma: A Systematic Review

Tang,

Taori,

Dang

et al. 2024

Otolaryngol.--head neck surg.

Self Cite

View full text Add to dashboard Cite

ObjectiveThe aim of this work is to comprehensively review and synthesize the literature related to sinonasal mucosal melanoma (SNMM) treatment with immunotherapy, including potentially targetable genetic mutations, survival outcomes, and adverse events.Data SourcesEmbase, Cochrane, Scopus, and Web of Science.Review MethodsThe study protocol was designed according to Preferred Reporting Items for Systematic Reviews and Meta‐analysis statement. Databases were searched from inception through May 23, 2023.ResultsA total of 42 studies met inclusion criteria. Twenty‐four of the included studies reported genetic mutations for a combined 787 patients with SNMM. 8.1% (95% confidence interval, CI: 7.6‐8.6), 18.9% (95% CI: 18.1‐19.8), and 8.5% (95% CI: 8.1‐9.0) of reported patients were positive for BRAF, NRAS, and KIT mutations, respectively. The presence of brisk tumor‐infiltrating lymphocytes was associated with improved recurrence‐free survival and overall survival (OS). Six studies reported a combined 5‐year OS after adjuvant immunotherapy treatment of 42.6% (95% CI: 39.4‐45.8). Thirteen studies encompassing 117 patients reported adjuvant or salvage immune checkpoint inhibitor (ICI) immunotherapy response rates: 40.2% (95% CI: 36.8‐43.6) had a positive response (tumor volume reduction or resolution). Eleven studies reported direct comparisons between SNMM patients treated with or without immunotherapy; the majority (7/11) reported survival benefit for their entire cohort or select subgroups of SNMM patients. With the transition to modern ICIs, there is a stronger trend toward survival improvement with adjuvant ICI. Tumors with Ki67 <40% may respond better to ICI's.ConclusionICI therapy can be an effective in select SNMM patients, especially those with advanced/metastatic disease.

show abstract

Section: Adjuvant and Salvage Immunotherapy Outcomes And Response Ratementioning

confidence: 99%

Immunotherapy in the Management of Sinonasal Mucosal Melanoma: A Systematic Review

Tang,

Taori,

Dang

et al. 2024

Otolaryngol.--head neck surg.

Self Cite

View full text Add to dashboard Cite

show abstract

International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

Kuan

Wang

Adappa

et al. 2024

Int Forum Allergy Rhinol

Self Cite

View full text Add to dashboard Cite

BackgroundSinonasal neoplasms, whether benign and malignant, pose a significant challenge to clinicians and represents a model area for multidisciplinary collaboration in order to optimize patient care. The International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors (ICSNT) aims to summarize the best available evidence and presents 48 thematic and histopathology‐based topics spanning the field.MethodsIn accordance with prior ICAR documents, ICSNT assigned each topic as an Evidence‐Based Review with Recommendations, Evidence‐Based Review, and Literature Review based on level of evidence. An international group of multidisciplinary author teams were assembled for the topic reviews using the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses format, and completed sections underwent a thorough and iterative consensus‐building process. The final document underwent rigorous synthesis and review prior to publication.ResultsThe ICNST document consists of 4 major sections: general principles, benign neoplasms and lesions, malignant neoplasms, and quality of life and surveillance. It covers 48 conceptual and/or histopathology‐based topics relevant to sinonasal neoplasms and masses. Topics with a high level of evidence provided specific recommendations, while other areas summarized the current state of evidence. A final section highlights research opportunities and future directions, contributing to advancing knowledge and community intervention.ConclusionAs an embodiment of the multidisciplinary and collaborative model of care in sinonasal neoplasms and masses, ICSNT was designed as a comprehensive, international, and multidisciplinary collaborative endeavor. Its primary objective is to summarize the existing evidence in the field of sinonasal neoplasms and masses.This article is protected by copyright. All rights reserved

show abstract

Outcomes of Immunotherapy in Sinonasal Mucosal Melanoma Patients With Recurrent and Metastatic Disease

Iyoha,

Jenkins,

Guo

et al. 2024

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

Sinonasal mucosal melanoma (SNMM) is a rare malignancy with poor prognosis and high recurrence rate. In those with recurrence, survival is dismal. Immunotherapy is an emerging area of investigation; however, there is a scarcity of data on immunotherapy outcomes in SNMM patients with recurrence. We report outcomes of immunotherapy in recurrent SNMM patients with distant versus nondistant recurrence. Fifty‐four patients with recurrent SNMM were identified, and 31 (57.4%) had distant recurrence. One‐year overall survival (OS) following recurrence was 47.5% (95% confidence interval [CI]: 34.0%‐60.9%), with a median survival of 2.8 years (95% CI: 2.0‐5.3). In those with distant recurrence, receipt of immunotherapy was associated with better OS compared to those without immunotherapy (hazard ratio [HR] = 0.29 [95% CI: 0.12‐0.68], P = .004). While patients with nondistant recurrence (n = 23), who received immunotherapy (n = 6) had worse OS compared to those who did not receive immunotherapy (HR = 4.76 [95% CI: 1.36, 15.89], P = .02).Level of EvidenceLevel IV.

show abstract

Recurrence patterns among patients with sinonasal mucosal melanoma: A multi‐institutional study

Cited by 5 publications

References 20 publications

Immunotherapy in the Management of Sinonasal Mucosal Melanoma: A Systematic Review

Immunotherapy in the Management of Sinonasal Mucosal Melanoma: A Systematic Review

International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

Outcomes of Immunotherapy in Sinonasal Mucosal Melanoma Patients With Recurrent and Metastatic Disease

Contact Info

Product

Resources

About